Mesirow Financial Investment Management, Inc. Halozyme Therapeutics, Inc. Transaction History
Mesirow Financial Investment Management, Inc.
- $4.9 Billion
- Q1 2025
A detailed history of Mesirow Financial Investment Management, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Mesirow Financial Investment Management, Inc. holds 10,446 shares of HALO stock, worth $581,215. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,446
Previous 19,494
46.41%
Holding current value
$581,215
Previous $932,000
28.54%
% of portfolio
0.01%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
595Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$980 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$714 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$337 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$217 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$204 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...